×
About 11,525,212 results

A silent epidemic
https://news.harvard.edu/gazette/story/2020/04/one-third-of-hospitalized-covid-19-patients-show-signs-of-delirium/
Stephanie Dutchen

Geriatrician Sharon Inouye on the need to combat delirium in COVID-19 patients

This coronavirus mutation has taken over the world. Scientists are trying to understand why.
https://www.washingtonpost.com/science/2020/06/29/coronavirus-mutation-science/?arc404=true

A mutation affecting the virus's spike protein changed amino acid 614 from “D” (aspartic acid) to “G” (glycine). Research suggests that this small change — which affects three identical amino acid chains — might make the spike protein more effective, enhancing the virus’s infectiousness.

Mutation Allows Coronavirus to Infect More Cells, Study Finds. Scientists Urge Caution.
https://www.nytimes.com/2020/06/12/science/coronavirus-mutation-genetics-spike.html

Geneticists said more evidence is needed to determine if a common genetic variation of the virus spreads more easily between people.

Neurologic Features in Severe SARS-CoV-2 Infection
https://www.nejm.org/doi/full/10.1056/NEJMc2008597

We report the neurologic features in an observational series of 58 of 64 consecutive patients admitted to the hospital because of acute respiratory distress syndrome (ARDS) due to Covid-19. The patients received similar evaluations by intensivists in two intensive care units (ICUs) in Strasbourg, France, between March 3 and April 3, 2020.

‘They Want to Kill Me’: Many Covid Patients Have Terrifying Delirium
https://www.nytimes.com/2020/06/28/health/coronavirus-delirium-hallucinations.html

To a startling degree, many coronavirus patients are reporting similar experiences. Called hospital delirium, the phenomenon has previously been seen mostly in a subset of older patients, some of whom already had dementia, and in recent years, hospitals adopted measures to reduce it.

Delirium Incidence, Duration and Severity in Critically Ill Patients with COVID-19
https://www.medrxiv.org/content/10.1101/2020.05.31.20118679v1.full.pdf

Delirium incidence, duration and severity in patients admitted to the intensive care unit (ICU) due to COVID-19 is not known.

Association between Olfactory Deficit and Motor and Cognitive Function in Parkinson’s Disease
https://www.e-jmd.org/upload/jmd-19082.pdf
Journal of Movement Disorders;

We recruited 228 drug-naïve PD patients who were followed for a mean of 6 years. Patients underwent the Cross-Cultural Smell Identification Test (CCSIT), a neuropsychological test, and N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane positron emission tomography within 6 months of the baseline evaluation. Olfactory dysfunction was categorized as normosmia (CCSIT score ≥ 9)...

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
https://www.frontiersin.org/articles/10.3389/fneur.2019.01217/full
Frontiers in Neurology;

Nov 20th, 2019 - The forefront treatment of Parkinson's disease (PD) is Levodopa. When patients are treated with Levodopa cerebral blood flow is increased while cerebral metabolic rate is decreased in key subcortical regions including the putamen. This phenomenon is especially pronounced in patients with Levodopa-induced dyskinesia (LID).

Expert Perspective on ASCO20 Genitourinary Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200232/full/

Jul 2nd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achieving sustained testosterone suppression. Additionally, treatment was associated with faster testosterone recovery and decreased major adverse cardiovas...

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-cell therapy, with 4-1BB costimulatory domain and CD3Z T-cell activation domain.

Expert Perspective on ASCO20 Gastrointestinal Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200231/full/

Jul 1st, 2020 - Donafenib, a deuterated derivative of sorafenib, was tested against sorafenib in the frontline setting in hepatitis B– associated hepatocellular carcinoma (HCC) in a large, multi-institutional study in China (Abstract 4506).

Expert Perspective on ASCO20 Gynecologic Oncology Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200233/full/

Jul 2nd, 2020 - DESKTOP III (Abstract 6000) is a prospective, multicenter, randomized phase III study of > 400 patients with platinum-sensitive, recurrent ovarian cancer that demonstrated a clinically meaningful 7.7 month improvement in median overall survival with secondary cytoreductive surgery (53.7 months) compared with no surgery (46 months).

Immunotherapy and Beyond: Treatment Options and Potential Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200227/full/

Jul 2nd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) carries a poor prognosis, with an overall survival (OS) of approximately 1 year.

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.50991
Annals of Clinical and Translational Neurology;

Feb 6th, 2020 - To investigate whether the burden of white matter hyperintensities (WMHs) is associated with the risk of developing levodopa‐induced dyskinesia (LID) in Parkinson’s disease (PD).

The impact of levodopa therapy-induced complications on quality of life in Parkinson’s disease patients in Singapore
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593098/

The objective of this study was to investigate the impact of levodopa therapy-induced complications on the quality of life (QoL) of Parkinson’s disease (PD) patients in Singapore over a 1-year follow-up period. 274 PD patients were prospectively recruited, of which 78 patients completed the follow-up. Patients were evaluated on: (1) motor symptoms, (2) non-motor symptoms, (3) levodopa therapy-i...

COVID-19 in Racial and Ethnic Minority Groups
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html
CDC

The effects of COVID-19 on the health of racial and ethnic minority groups is still emerging; however, current data suggest a disproportionate burden of illness and death among racial and ethnic minority groups. A recent CDC MMWR report included race and ethnicity data from 580 patients hospitalized with lab-confirmed COVID-19 found that 45% of individuals for whom race or ethnicity data was av...

Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30264-3/fulltext
The Lancet Public Health;

The risk of severe COVID-19 if an individual becomes infected is known to be higher in older individuals and those with underlying health conditions. Understanding the number of individuals at increased risk of severe COVID-19 and how this varies between countries should inform the design of possible strategies to shield or vaccinate those at highest risk.

An Oral History of Coronavirus: Testimonies about the pandemic
https://www.washingtonpost.com/graphics/2020/national/coronavirus-oral-history/

An Oral History of COVID-19 From Doctors & Frontline Workers

Dr. Usmani on Activity of Teclistamab in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/dr-usmani-on-activity-of-teclistamab-in-relapsed-refractory-multiple-myeloma

May 30th, 2020

Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC
https://www.onclive.com/view/robust-data-and-multivariate-analyses-support-cabazitaxel-as-a-standard-of-care-in-mcrpc

May 30th, 2020